Pregabalin, an ␣2␦ ligand, is used clinically to treat somatic pain. A prior study suggested that pregabalin reduces distension-induced pain while increasing rectal compliance. We aimed to quantify effects of pregabalin on colonic sensory and motor functions and assess relationships between sensory effects and colonic compliance. We conducted a randomized, double-blind, placebo-controlled, parallel-group study of a single oral administration of 75 or 200 mg of pregabalin in 62 healthy adults (aged 18 -75 yr). Subjects underwent left colon intubation. We assessed "stressarousal symptoms", compliance, sensation thresholds, sensation ratings averaged over four levels of distension, fasting and postprandial colonic tone, and phasic motility index (MI). Analysis of covariance (adjusted for age, sex, body mass index, and corresponding predrug response) and proportional hazard models were used. There were no clinically important differences among treatment groups for demographics, predrug compliance, tone, MI, and sensation. Treatment was associated with reduced energy and increased drowsiness but no change in tension or relaxation. Sensation ratings averaged over the four distension levels were lower for gas sensation [overall effect P ϭ 0.14, P ϭ 0.05 (pregabalin 200 mg vs. placebo)] and for pain sensation [overall effect P ϭ 0.12, P ϭ 0.04 (pregabalin 200 mg vs. placebo)]. The magnitude of the effect of 200 mg of pregabalin relative to placebo is on average a 25% reduction of both gas and pain sensation ratings. Pregabalin did not significantly affect colonic compliance, sensation thresholds, colonic fasting tone, and MI. Thus 200 mg of pregabalin reduces gas and pain sensation and should be tested in patients with colonic pain. colonic compliance; gas sensation; pain sensation THE HETEROMULTIMERIC voltage-sensitive calcium (Ca 2ϩ ) channel is involved in the function of excitable tissues including sensory nerves. It comprises a primary ␣1 subunit and auxiliary ␣2␦, , and ␥ subunits, and the associated ␣2␦ ligandbinding site (26). Pregabalin binds potently to the ␣2␦ auxiliary protein associated with voltage-gated calcium channels (12), reducing depolarization-induced calcium influx at the nerve terminals. Consequently, pregabalin may reduce the release of several excitatory neurotransmitters, including glutamate, noradrenaline, substance P, and calcitonin gene-related peptide, which have been involved in pain mechanisms (1, 4). Recently, Needham et al. (21) showed that intrinsic primary afferent neurons in the small bowel of guinea pigs express functional N (␣1B) channel-forming subunits that are associated with ␣2␦1 modulatory subunits and are inhibited by pregabalin.Pregabalin, a second generation ␣ 2 ␦ ligand, has been shown to be effective in several animal models of visceral pain including trinitrobenzene sulfonic acid colitis (10), septic shock-induced rectal hypersensitivity (11), and a repeated colonic distension model in normal rat colon (20). These studies led to pregabalin being proposed as a trea...